Arnie Gundersen is freaking me out! Gundersen is no tin-foil hat guy, he’s the chief engineer of energy consulting company Fairewinds Associates and a former nuclear power industry executive who served as an expert witness in the investigation of the Three Mile Island accident. Gundersen has said that the U.S. nuclear industry and regulators need to reexamine disaster planning and worst-case scenarios, especially in reactors such as Vermont Yankee, which have the same design as the crippled nuclear plant at the center of the 2011 Japanese Fukushima nuclear emergency. Vermont Yankee and similar plants are vulnerable to a similar cascade of events as in Japan.
The Nikkei had fallen down to 8,227 from 10,678 (23%) at the quake and has since recovered 10,017 on May 2nd but was back to 9,648 on Friday (3.6% off the bounce) and the 50 dma has now formed an aptly-named "death cross" below the 200 dma. Japan is already on the hook for $124Bn from the earthquake and will also have to cover TEPCO’s $31Bn (so far) liability as the alternative is let the country’s biggest energy supplier go bankrupt and that would be lights out on their economy.
Warning: Do not watch this video on a full stomach:
Accident is a funny word isn’t it? With 435 active plant and 250 more under construction, even if they are 99.9% safe, that would still mean we get an accident like this every year. Hopefully they are 99.99% safe and we only have a major catastrophe every 10 years – wouldn’t that be nice but, so far, that’s not the case as we’ve had about 16 in 50 years with 9 of those considered "major." So accident applies to this situation in the same way…
Leaked water believed contain radation in a photo released by Tokyo Electric Power Company on April 2.
Sawdust. It’s not the first thing most people would choose to put between themselves and highly contaminated radioactive water. But a mixture of sawdust — ogakuzu in Japanese — with chemicals and shredded newspaper is precisely what nuclear safety authorities and power plant officials turned to in trying to plug a 8-inch crack in a shaft near reactor 2 at the Daiichi nuclear power plant in Fukushima over the weekend.
Unfortunately, like the concrete they tried before it, the sawdust didn’t work, and as of Monday, the flow of irradiated water into the sea from the shaft continued unabated. “We have not succeeded yet,” Ken Morita, director of the international affairs office at Japan’s Nuclear and Industrial Safety Agency (NISA), acknowledged to TIME on Monday morning. “We will try again today.”
What will they try next? For the past three weeks, that has been the question hovering in the irradiated air above Fukushima, where each passing day seems to bring a new and unprecedented challenge for the ebattled Tokyo Electric Power Company (TEPCO) to shut down the reactors at the Fukushima nuclear power plant safely.
Since Saturday, when TEPCO announced that workers had detected radioactive water flowing directly into the ocean, the crisis of the hour has been stopping and mitigating the impact of the newly found leak. On Saturday, NISA said it had found seawater about 25 miles south of Fukushima contained twice the normal limits of radioactive iodine. Officials say dye has now been added into the water to be able to trace the movement of leaked radioactive particles, and that workers will be setting up a physical barrier near the plant to try to stop their flow out of the direct area. “There are many important things to do, but in this current situation, many people are focusing on stopping the outflow,” says Morita. “Many options are now under consideration but we have not decided on anything.”
That kind of opacity — whether a symptom of sheer improvisation or a more calculated attempt to cloak the severity of an unsolved problem — has not won TEPCO, or the Japanese authorities, any fans in the international nuclear community. Without more information about what is happening at the crippled plant, nuclear experts outside
Radiation levels that can prove fatal were detected outside reactor buildings at Japan’s Fukushima Dai-Ichi plant for the first time, complicating efforts to contain the worst disaster since Chernobyl in 1986.
Water in an underground trench outside the No. 2 reactor had levels exceeding 1 sievert an hour, a spokesman for plant operator Tokyo Electric Power Co. told reporters in the capital yesterday. Exposure to that dose for 30 minutes would trigger nausea and four hours might lead to death within two months, according to the U.S. Environmental Protection Agency.
Preventing the most-contaminated water from leaking into the ground or air is key to containing the spread of radiation beyond the plant. A partial meltdown of fuel rods in the No. 2 reactor probably caused a jump in the readings, Japan’s chief government spokesman said.
“There’s not much good news right now,” said Gennady Pshakin, a former IAEA official based in Obninsk, the site of Russia’s first nuclear power plant. “There’re questions arising on how much fuel will leak out, what isotopes will be carried and how quickly they will settle. It’s becoming less predictable.”
Tokyo Electric Power Co. found plutonium in soil samples taken near the stricken Fukushima Dai- Ichi nuclear plant a week ago, the company said.
The presence of plutonium outside the plant means there’s been degradation of the fuel in at least one of the six reactors, Denis Flory, deputy director general of safety at the International Atomic Energy Agency, said yesterday at a press briefing in Vienna. Tokyo Electric can’t determine which reactor emitted plutonium, Vice President Sakae Muto said in a briefing shown on a webcast.
The contamination “shouldn’t have any effect on human health,” Muto said.
Soil chemistry may determine whether the plutonium can spread from the site, Edwin Lyman, a radiological specialist for the Union of Concerned Scientists, said on a conference call. Some compounds formed by plutonium are water soluble, and some aren’t, he said.
IAEA Director General Yukiya Amano said there are “mixed signals” coming from emergency repair efforts at Fukushima. “The situation continues to be very serious,” Amano said in Vienna yesterday.
"That concerns me," says one of our nation’s top monetary strategists. The regional bank chief said he personally surveys about 50 businesses, more than most of his colleagues at the Fed, and that the position on prices is “without exception, in every sector in every size, whether they’re public or private.”
While I guess we should applaud Fisher for being the first Fed Governor to recognize inflation in our economy – I suppose I should also point out to the Fed that there is a preponderance of evidence that indicates, at this point, that the Earth is not flat – just to help them get caught up with the rest of us. Still Fisher is somewhat of a prodigy among the slim pickings we have when selecting from Fed brains:
Barring some extraordinary circumstances I cannot foresee, I would vote against the QE3 or even a tapering of the current program. I don’t think it’s necessary, It’s now up to the fiscal authorities to provide the right incentives for businesses to hire more American people, Our job is done. Now the pressure and the job is in the hands of our elected representatives who have the only power to tax and to spend.
TAX and spend?!? Oh no he didn’t! That’s Liberal Commie talk if ever I heard it and, if the Fed is going to base their own policy on the assumption that this Government will either tax OR spend – then we are already doomed because the Keynesians left the building last November and are unlikely to be invited back in until we have our own nuclear melt-down to throw money at (or if the banks need money, of course).
This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible. Feel free to contact me directly at email@example.com with any questions.
Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts. After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.) Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.
The Environmental Protection Agency is considering a review of its 1977 rule that limits the amount of whole-body radiation that any member of the public can be exposed to as a result of the uranium fuel cycle.
While they have not made any immediate determination to change the current level of 0.25 millisieverts per year of allowable radiation, they are reviewing the scientific data to decide if changes need to be made.
Items under review include water resource protection, spent fuel storage facilities and alternative technologie...
“What the government is good at is collecting taxes, taking away your freedoms and killing people. It’s not good at much else.” —Author Tom Clancy
Call it what you will—taxes, penalties, fees, fines, regulations, tariffs, tickets, permits, surcharges, tolls, asset forfeitures, foreclosures, etc.—but the only word that truly describes the constant bilking of the American taxpayer by the government and its corporate partners is th...
Earlier today, and several times recently, I received emails accusing me of being a Russian spy and asking me how much I was receiving from RT. I find such accusations highly amusing.
Here's the deal: Few bloggers are willing to discuss MH17 for fear of getting it wrong. Whereas I suspect nearly everything, but especially reports coming from Kiev and the US. My reasons are threefold:
There are more questions surrounding Kiev and US reports than Russian reports.
Kiev has been caught twice in lies and distortions
While neither US nor Russia is unbiased, the extremely one-sided, jump-to-conclusion reporting from Western media suggests close consideration of competing versions of stories is warranted.
The pre-open release of the Consumer Price Index showed core inflation in June to be a tad lighter than forecasts. The S&P 500 opened at its 0.10% intraday low and rallied to its 0.64% record intraday high about ninety minutes into the session. Strong existing home sales announced at 10 AM certainly helped. The index spent the rest of the day in a narrow trading range and closed with a 0.50% gain, a mere 0.10% off its record close of July 3rd.
The yield on the 10-year note ended the day at 2.48%, 1 bp below yesterday's close. It is now only 4 bps above its interim closing low of May 28th.
Here is a 15-minute chart of the past five sessions. The S&P 500 is up 7.31% year-to-date.
A large call spread initiated on Orexigen Therapeutics, Inc. (Ticker: OREX) on Monday morning looks for shares in the name to rally approximately 30% by September expiration. The September expiration is noteworthy as the company awaits the results of the FDA’s review of its resubmitted New Drug Application (NDA) for NB32, an investigational medication being evaluated for weight loss, after the review was extended for three months back in June. The upcoming Prescription Drug User Fee Act (PDUFA) date is September 11, 2014, according to a press release issued by the company. Shares in Orexigen today are up roughly 0.40% at $5.34 as of 2:15 p.m. ET.
Despite a highly eventful week in the news, not much has changed from a stock market perspective. No doubt, investors have grown immune to the daily reports of geopolitical turmoil, including Ukraine vs. Russia for control of the eastern regions, Japan’s dispute with China over territorial waters, Sunni vs. Shiite for control of Iraq, Christians being driven out by Islamists, and other religious conflicts in places like Nigeria and Central African Republic. But last Thursday’s news of the Malaysian airliner tragically getting shot down over Ukraine, coupled with Israel’s ground incursion into Gaza, had the makings of a potential Black Swan event, which in my view is the only thing that could derail the relentless bull march higher in stocks.
Nevertheless, when it became clear that the airline...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
We tried holding up stock prices but couldn’t get the job done. Market Shadows’ Virtual Value Portfolio dipped by 2% during the week but still holds on to a market-beating 8.45% gain YTD. There was no escaping the downdraft after a major Portuguese bank failed. Of all the triggers for a large selloff, I’d guess the Portuguese bank failure was pretty far down most people's list of "things to worry about."
All three major indices gave up some ground with the Nasdaq composite taking the hardest hi...
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Well PSW Subscribers....I am still here, barely. From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired....buy a small amount.
First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices. Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment. Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer. For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND...
I just wanted to be sure you saw this. There’s a ‘live’ training webinar this Thursday, March 27th at Noon or 9:00 pm ET.
If GOOGLE, the NSA, and Steve Jobs all got together in a room with the task of building a tremendously accurate trading algorithm… it wouldn’t just be any ordinary system… it’d be the greatest trading algorithm in the world.
Well, I hate to break it to you though… they never got around to building it, but my friends at Market Tamer did.
Note: The material presented in this commentary is provided for
informational purposes only and is based upon information that is
considered to be reliable. However, neither MaddJack Enterprises, LLC
d/b/a PhilStockWorld (PSW) nor its affiliates
warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.